CN107337731A - A kind of composite yolk antibody powder and its preparation production method for anti-dog and cat diarrhea - Google Patents
A kind of composite yolk antibody powder and its preparation production method for anti-dog and cat diarrhea Download PDFInfo
- Publication number
- CN107337731A CN107337731A CN201710543777.6A CN201710543777A CN107337731A CN 107337731 A CN107337731 A CN 107337731A CN 201710543777 A CN201710543777 A CN 201710543777A CN 107337731 A CN107337731 A CN 107337731A
- Authority
- CN
- China
- Prior art keywords
- antibody
- yolk antibody
- yolk
- composite
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002969 egg yolk Anatomy 0.000 title claims abstract description 100
- 239000000843 powder Substances 0.000 title claims abstract description 48
- 239000002131 composite material Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 241000282326 Felis catus Species 0.000 title abstract description 32
- 206010012735 Diarrhoea Diseases 0.000 title description 24
- 238000004519 manufacturing process Methods 0.000 title description 6
- 230000002953 anti-rotaviral effect Effects 0.000 claims abstract description 13
- 241000711573 Coronaviridae Species 0.000 claims abstract description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 5
- 229940067606 lecithin Drugs 0.000 claims abstract description 5
- 235000010445 lecithin Nutrition 0.000 claims abstract description 5
- 239000000787 lecithin Substances 0.000 claims abstract description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 17
- 108010000912 Egg Proteins Proteins 0.000 claims description 17
- 241000125945 Protoparvovirus Species 0.000 claims description 15
- 235000013345 egg yolk Nutrition 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 241000702670 Rotavirus Species 0.000 claims description 12
- 235000013601 eggs Nutrition 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 108700010904 coronavirus proteins Proteins 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 108010000916 Fimbriae Proteins Proteins 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 101710146739 Enterotoxin Proteins 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000000147 enterotoxin Substances 0.000 claims description 2
- 231100000655 enterotoxin Toxicity 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims 1
- 206010040829 Skin discolouration Diseases 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 208000017520 skin disease Diseases 0.000 abstract description 2
- 206010004016 Bacterial diarrhoea Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000010717 cat disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 244000309720 Escherichia coli F4 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000710914 Totivirus Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of composite yolk antibody powder and preparation method thereof and preparation, anti-parvovirus antibody, Antibodies against coronavirus, anti-rotavirus antibody and anti-enterotoxigenicEscherichia coli tetravalent antibody are contained in the composite yolk antibody powder.Composite yolk antibody powder of the present invention can not only prevent and treat dog cat bacterial diarrhea, the use of substitute antibiotics, the morbidity and mortality of reduction dog cat；The lecithin contained simultaneously, the bright hair of dog cat skin lightening can be promoted, reduce skin disease.
Description
Technical field
The invention belongs to veterinary drug and biomedicine technical field, and in particular to be a kind of compound ovum for anti-dog and cat diarrhea
Yellow antibody powder and its preparation production method.
Background technology
As the most important companion animals of the mankind, dog cat plays key player in our life.However, in state
Interior, the control and prevention of disease research of dog cat is serious to be lagged；Dog cat suffer from answering for a variety of unfavorable factors in our living environment
Swash the invasion and attack with cause of disease, the diarrhoea problem of large effect, particularly dog cat is generated to its gastrointestinal health situation.Cause dog
Cat disease originality diarrhoea is more common in the infection such as parvovirus, coronavirus and rotavirus, the also pathogenic enterotoxin type of conditionity
Coli-infection；The former is due to being virus diarrhea, using antibiotic ineffective, the latter due to Escherichia coli drug resistance too
By force, it is also undesirable using the effect of antibiotic, so cause the diarrhoea prevention difficulty of dog cat to increase.Therefore, how to prevent and control
The generation of dog and cat diarrhea disease is treated, reduces the morbidity and mortality of dog cat, reduces or cancels the use of antibiotic medicine, give
Dog cat disease study on prevention person proposes series of studies problem.
In recent years, have been reported that and the egg-yolk antibody powder containing antibody is prepared using the method for preparing Yolk antibody, make an addition to feeding
Feeding animals in material or other active medicines, the disease with popularity can be directed to and play certain prevention effect, improved dynamic
The resistance against diseases of thing.For example, patent application 200810217587.6 discloses a kind of economic benefits and social benefits valency for containing anti-porcine CCK/Urease
Powdery yolk of Yolk antibody and preparation method thereof；Patent application 201710037459.2 discloses a kind of for preventing and treating weanling pig
Pharmaceutical composition of diarrhoea and its preparation method and application.However, for dog cat relevant common disease prevent additive still
Have no report.In addition, inventor has found under study for action, in the preparation method of Yolk antibody, generally use totivirus and complete thin
Bacterium is inactivated to prepare antigen, so that laying hen to be immunized, however, such processing causes antigentic specificity not strong, antibody effect
Valency is relatively low, and using effect is poor, and use cost is high, and commercial application value is little.Therefore, still need to change to preparing production method
Enter.
The content of the invention
In order to solve the above technical problems, inventor is first to influenceing dog cat health status, especially gastrointestinal health situation
Factor screened, select parvovirus, coronavirus, rotavirus and Escherichia coli F4 F5 F6 the tetravalence pili of F 18
The recombinant antigen of albumen laying hen is immunized respectively as immunogene, again necessarily to compare after egg-yolk antibody powder is obtained
Example is mixed, and can obtain the composite yolk antibody powder that can be prevented (mainly for diarrhoea) dog cat common disease, from
And complete the present invention.
Therefore, in one aspect, the invention provides a kind of composite yolk antibody powder, contain in the composite yolk antibody powder
There are anti-parvovirus antibody, Antibodies against coronavirus, anti-rotavirus antibody and anti-enterotoxigenicEscherichia coli tetravalent antibody.
The anti-enterotoxigenicEscherichia coli tetravalent antibody includes anti-F4 Escherichia coli antibody, F5 Escherichia coli antibody, F6 Escherichia coli
Antibody, F18 Escherichia coli antibody.
Preferably, in the composite yolk antibody powder,
Anti- parvovirus antibody titre >=1600:1；
Antibodies against coronavirus titre >=1600:1；
Anti-rotavirus antibody titer >=1600:1；
Anti- enterotoxigenicEscherichia coli tetravalent antibody titre >=1600:1.
The lecithin content in the composite yolk antibody powder of the present invention is measured using following methods：
(a) preparation of standard items:Standard items are dissolved in methanol/chloroform (1 first:1) in solution, it is about 2 that concentration, which is made,
The solution of mg/ml, then the concentration of standard solution is halved in order, it is intended to for each analysis thing provide 78 to
10000ng O.C. calibration range；
(b) preparation of powdery yolk sample：Weigh 90.3 milligrams of powdery yolks to pour into 2 milliliters of vials, add 150 microlitres of first
Alcohol chloroform (1:1) solution, vortex mixing；Add 500 microlitres of acetonitriles, vortex mixing, it is intended to make albumen precipitation；Add 1350
Microlitre methanol/chloroform (1:1) solution, vortex mixing and is allowed to rest for；Finally pipette supernatant and entered with 10000 grams × 3 minutes
Row centrifugation, then pipette supernatant and carry out HPLC detections；
(c) data analysis:HPLC system used in this measure is hermo ScientificTM Hypersil、GOLDTM
Silica column, data use Thermo ScientificTM DionexTM ChromeleonTM Chromatography
Data System softwares are arranged and analyzed.
Preferably, by weight, lecithin content is 8%-12% in the composite yolk antibody powder.
Preferably, by weight, the anti-parvovirus egg yolk antibodies of 10-50%, 10- are included in the composite yolk antibody powder
50% anti-coronavirus Yolk antibody, 10-50% anti-rotavirus Yolk antibody, the anti-enterotoxigenicEscherichia colis four of 10-50%
Valency Yolk antibody and 1-2% antagonists, each component sum are 100%.The antagonist is preferably silica.
In another aspect, present invention also offers the preparation method of the composite yolk antibody powder, methods described to include
Following steps：
It is prepared by a immunogenes：By parvovirus, coronavirus, rotavirus and enterotoxigenicEscherichia coli F4 F5 F6
The recombinant antigen of F18 tetravalence pilins adds adjuvant that parvovirus immunogene, coronavirus protein immunogens, rotavirus is respectively prepared
Immunogene and enterotoxigenicEscherichia coli tetravalence immunogene；
B laying hens are immunized：With the parvovirus immunogene, coronavirus protein immunogens, rotavirus immunogene and intestines
Laying hen is immunized respectively for toxin type Escherichia coli tetravalence immunogene, is inoculated with 3 times, and Yolk antibody titre is detected through ELISA
≥16000:After 1, start to collect egg；
The preparation of c egg-yolk antibody powders：By the egg it is cleaned, beat eggs separation after obtain yolk, through homogeneous, pasteurize
Afterwards, it is then spray-dried, anti-parvovirus egg yolk antibody, anti-coronavirus Yolk antibody, anti-rotavirus yolk are obtained respectively
Antibody, anti-enterotoxigenicEscherichia coli tetravalence Yolk antibody；
The preparation of d composite yolk antibody powder：By the anti-parvovirus egg yolk antibody, anti-coronavirus Yolk antibody, resist
Rotavirus Yolk antibody, anti-enterotoxigenicEscherichia coli tetravalence Yolk antibody mix with antagonist, obtain composite yolk antibody
Powder.
Wherein, the adjuvant in step a can be any kind of adjuvant, preferably Freund's adjuvant.
Preferably, in step c, yolk homogeneous, 50-68 DEG C of pasteurize 3-6 minute under 8-16Mpa pressure, then
It is spray-dried under the conditions of 120-200 DEG C of air intake, 50-80 DEG C of air draft, obtains anti-parvovirus egg yolk antibody respectively, resists coronal disease
Malicious Yolk antibody, anti-rotavirus Yolk antibody, anti-enterotoxigenicEscherichia coli tetravalence Yolk antibody.
In yet another aspect, present invention also offers the preparation for including composite yolk antibody powder of the present invention, the system
Agent is paste, electuary or microcapsules.The paste, electuary or microcapsules can be made by method well known to those skilled in the art
It is standby.
Beneficial effect：
The composite yolk antibody powder for anti-dog and cat diarrhea of the present invention, while comprising antiviral antibody and bacterial antibodies, can
All kinds of diarrhoea of dog cat are fully and effectively prevented and treated, reduce the use of even substitute antibiotics, reduces the morbidity of diarrhoea
Rate and the death rate of dog cat.
On the other hand, the fur of dog cat is the influence for protecteding from extraneous hostile environment, maintains normal body temperature, resistance disease
The important barrier of substance infringement.The health status of fur is the key character of dog cat, and magnificent fur is the second of pet dog cat
Life.In the market, the ordinary nutritional material of the bright hair of dog cat skin lightening is helped mainly to have protein, fat, amino acid, vitamin
Deng.And also contain lecithin in the composite yolk antibody powder of the present invention, the bright hair of dog cat skin lightening can be promoted, reduce skin disease.
Embodiment
Embodiment 1
It is used for the scale of the composite yolk antibody powder of anti-dog and cat diarrhea according to production 100kg, is given birth to using following steps
Production：
It is prepared by a immunogenes：By parvovirus, coronavirus, rotavirus and enterotoxigenicEscherichia coli F4 F5
F6 the recombinant antigens of F18 tetravalence pilins add Freund's adjuvant, be respectively prepared parvovirus immunogene, coronavirus protein immunogens,
Rotavirus immunogene and enterotoxigenicEscherichia coli tetravalence immunogene, wherein, the enterotoxigenicEscherichia coli tetravalence is immunized
Originally it was the tetravalence immunogene for including F4/F5/F6/F18 bacillus coli antigens that genetic engineering obtains；
B laying hens are immunized：With the parvovirus immunogene, coronavirus protein immunogens, rotavirus immunogene and intestines
Laying hen is immunized respectively for toxin type Escherichia coli tetravalence immunogene, is inoculated with 3 times, and Yolk antibody titre is detected through ELISA
≥16000:After 1, start to collect egg；
The preparation of c egg-yolk antibody powders：The egg is obtained into yolk after automatic washing, separation of beating eggs, in 12Mpa
Homogeneous under pressure, 68 DEG C of pasteurizes 3 minutes, then be spray-dried under the conditions of 180 DEG C of air intake, 70 DEG C of air draft, resisted respectively
Parvovirus egg yolk antibody, anti-coronavirus Yolk antibody, anti-rotavirus Yolk antibody, anti-enterotoxigenicEscherichia coli tetravalence
Yolk antibody；
The preparation of d composite yolk antibody powder：By anti-parvovirus egg yolk antibody, 25kg anti-coronavirus ovum described in 25kg
Yellow antibody, 23kg anti-rotavirus Yolk antibody, the anti-enterotoxigenicEscherichia coli tetravalence Yolk antibodies of 25kg and 2kg silica
Mixing, obtain composite yolk antibody powder.
EXPERIMENTAL EXAMPLE 1
In this EXPERIMENTAL EXAMPLE, the preventive effect that the composite yolk antibody powder of the present invention is suffered from diarrhoea to pup have studied.
1st, test method：Body weight and pup 160 similar in age in days are selected, is randomized into control group and test group, wherein
Test group 80, control group 80,30 days experimental periods.Composite yolk antibody of the test group feeding containing 0.2% embodiment of the present invention 1
The feed of powder, control group fed normal diet, two groups of feeding managements are identical.
2nd, result of the test：Result of the test is as shown in table 1.
Table 1
As can be seen from the above results, test group improves 6.25% compared with control group survival rate, and diarrhea disease percentage reduces
10%, therefore, composite yolk antibody powder of the invention have effectively achieved the prevention to pup diarrhoea, improve survival rate.
EXPERIMENTAL EXAMPLE 2
In this EXPERIMENTAL EXAMPLE, clinical efficacy of the composite yolk antibody powder to young cat of suffering from diarrhoea of the present invention have studied.
1st, test method：Beijing cat house, chooses clinical young cat 60 of suffering from diarrhoea, and cat enteron aisle hat is diagnosed as through laboratory PCR
Shape virus infection, is randomized into test group and control group, wherein：Test group 30, control group 30, treatment phase are 5 days, experiment
Group is by the composite yolk antibody powder of the Standard Oral embodiment of the present invention 1 of 2g/kg body weight, oral probiotics (of control group
According to bacillus) treated.
2nd, result of the test：Result of the test is as shown in table 2.Wherein, completely cure refer to be discontinued after in 2 days without vomiting and diarrhoea disease
Shape, young cat spirit and appetite return to normal；Diarrhoea improvement refers to that water just switchs to loose stools, and water content greatly reduces.
Table 2
| Project | Test group | Control group |
| Experiment number of elements | 30 | 30 |
| Number of elements is cured completely | 27 | 11 |
| Diarrhoea improvement number of elements | 2 | 6 |
| Dead number of elements | 1 | 13 |
| Cure rate (%) | 90.0% | 36.67% |
| The death rate (%) | 3.33% | 43.33% |
As can be seen from the above results, test group improves 53.33% compared with cure rate in control group 5 days, and the death rate reduces
40%, significant difference, therefore, composite yolk antibody powder of the invention have effectively achieved the treatment to young cat diarrhea disease,
Substantially increase cure rate.
In addition, compared to the dog cat of feeding normal diet, feeding with the addition of the feed of the composite yolk antibody powder of the present invention
Dog cat, hair is substantially shinny.
The general principle and principal character and advantages of the present invention of the present invention has been shown and described above.The technology of the industry
For member it should be appreciated that the present invention is not limited to the above embodiments, described in above-described embodiment and specification is to illustrate this hair
Bright principle, without departing from the spirit and scope of the present invention, various changes and modifications of the present invention are possible, these changes
It all fall within the protetion scope of the claimed invention with improvement.The claimed scope of the invention is by appended claims and its waits
Effect thing defines.
Claims (10)
1. a kind of composite yolk antibody powder, it is characterised in that contain anti-parvovirus antibody in the composite yolk antibody powder, resist
Coronavirus antibody, anti-rotavirus antibody and anti-enterotoxigenicEscherichia coli tetravalent antibody.
2. composite yolk antibody powder according to claim 1, it is characterised in that the anti-enterotoxigenicEscherichia coli tetravalence
Antibody includes anti-F4 Escherichia coli antibody, F5 Escherichia coli antibody, F6 Escherichia coli antibody, F18 Escherichia coli antibody.
3. composite yolk antibody powder according to claim 1, it is characterised in that in the composite yolk antibody powder,
Anti- parvovirus antibody titre >=1600:1；
Antibodies against coronavirus titre >=1600:1；
Anti-rotavirus antibody titer >=1600:1；
Anti- enterotoxigenicEscherichia coli tetravalent antibody titre >=1600:1.
4. composite yolk antibody powder according to claim 1, it is characterised in that by weight, the composite yolk antibody
Lecithin content is 8%-12% in powder.
5. composite yolk antibody powder according to claim 1, it is characterised in that by weight, the composite yolk antibody
The anti-parvovirus egg yolk antibodies of 10-50%, 10-50% anti-coronavirus Yolk antibody, 10-50% anti-rotavirus are included in powder
The anti-enterotoxigenicEscherichia coli tetravalence Yolk antibody of Yolk antibody, 10-50% and 1-2% antagonists, each component sum are
100%.
6. composite yolk antibody powder according to claim 1, it is characterised in that the antagonist is silica.
7. the preparation method of the composite yolk antibody powder any one of claim 1-6, the described method comprises the following steps：
It is prepared by a immunogenes：By parvovirus, coronavirus, rotavirus and enterotoxigenicEscherichia coli F4 F5 F6 F18
The recombinant antigen of tetravalence pilin adds adjuvant that parvovirus immunogene, coronavirus protein immunogens, rotavirus is respectively prepared to exempt from
Epidemic focus and enterotoxigenicEscherichia coli tetravalence immunogene；
B laying hens are immunized：With the parvovirus immunogene, coronavirus protein immunogens, rotavirus immunogene and enterotoxin
Laying hen is immunized respectively for type Escherichia coli tetravalence immunogene, is inoculated with 3 times, through ELISA detection Yolk antibodies titre >=
16000:After 1, start to collect egg；
The preparation of c egg-yolk antibody powders：By the egg it is cleaned, beat eggs separation after obtain yolk, after homogeneous, pasteurize,
It is spray-dried again, anti-parvovirus egg yolk antibody, anti-coronavirus Yolk antibody, anti-rotavirus yolk are obtained respectively to be resisted
Body, anti-enterotoxigenicEscherichia coli tetravalence Yolk antibody；
The preparation of d composite yolk antibody powder：By the anti-parvovirus egg yolk antibody, anti-coronavirus Yolk antibody, anti-colyliform
Viral Yolk antibody, anti-enterotoxigenicEscherichia coli tetravalence Yolk antibody mix with antagonist, obtain composite yolk antibody powder.
8. according to the method for claim 7, it is characterised in that the adjuvant in step a is Freund's adjuvant.
9. the method according to claim 7 or 8, it is characterised in that in step c, the yolk is equal under 8-16Mpa pressure
Matter, 50-68 DEG C of pasteurize 3-6 minute, then be spray-dried under the conditions of 120-200 DEG C of air intake, 50-80 DEG C of air draft, obtain respectively
Parvovirus egg yolk antibody, anti-coronavirus Yolk antibody, anti-rotavirus Yolk antibody, anti-enterotoxigenicEscherichia coli must be resisted
Tetravalence Yolk antibody.
10. including the preparation of the composite yolk antibody powder any one of claim 1-6, the preparation is paste, electuary
Or microcapsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710543777.6A CN107337731A (en) | 2017-07-05 | 2017-07-05 | A kind of composite yolk antibody powder and its preparation production method for anti-dog and cat diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710543777.6A CN107337731A (en) | 2017-07-05 | 2017-07-05 | A kind of composite yolk antibody powder and its preparation production method for anti-dog and cat diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107337731A true CN107337731A (en) | 2017-11-10 |
Family
ID=60219578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710543777.6A Pending CN107337731A (en) | 2017-07-05 | 2017-07-05 | A kind of composite yolk antibody powder and its preparation production method for anti-dog and cat diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107337731A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109293753A (en) * | 2018-09-29 | 2019-02-01 | 赛法特（长沙）生物技术有限公司 | A kind of enterotoxigenicEscherichia coli tetravalence dynein immunogene and preparation method thereof |
| CN112996808A (en) * | 2018-10-03 | 2021-06-18 | 埃努贝尔拜欧公司 | Compositions and methods for treating acute diarrhea and intestinal infections in animals |
| CN114835804A (en) * | 2022-05-19 | 2022-08-02 | 安徽中起生物科技有限公司 | Feline infectious peritonitis egg yolk antibody composition and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104001171A (en) * | 2014-05-26 | 2014-08-27 | 黄光东 | Preparation method of compound IgY for preventing various diarrheas of piglets |
| CN105884889A (en) * | 2016-04-18 | 2016-08-24 | 内蒙古神元生物工程股份有限公司 | Canine distemper/infectious hepatitis/parvovirus triple egg yolk antibody and preparation method thereof |
-
2017
- 2017-07-05 CN CN201710543777.6A patent/CN107337731A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104001171A (en) * | 2014-05-26 | 2014-08-27 | 黄光东 | Preparation method of compound IgY for preventing various diarrheas of piglets |
| CN105884889A (en) * | 2016-04-18 | 2016-08-24 | 内蒙古神元生物工程股份有限公司 | Canine distemper/infectious hepatitis/parvovirus triple egg yolk antibody and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张绍兰: "鸡卵黄抗体研究进展", 《西南军医》 * |
| 郑根华等: "卵黄抗体治疗仔猪大肠杆菌感染性腹泻及其机理研究进展", 《中国兽医杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109293753A (en) * | 2018-09-29 | 2019-02-01 | 赛法特（长沙）生物技术有限公司 | A kind of enterotoxigenicEscherichia coli tetravalence dynein immunogene and preparation method thereof |
| CN112996808A (en) * | 2018-10-03 | 2021-06-18 | 埃努贝尔拜欧公司 | Compositions and methods for treating acute diarrhea and intestinal infections in animals |
| CN114835804A (en) * | 2022-05-19 | 2022-08-02 | 安徽中起生物科技有限公司 | Feline infectious peritonitis egg yolk antibody composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thu et al. | Chicken egg yolk antibodies (IgY) for prophylaxis and treatment of rotavirus diarrhea in human and animal neonates: a concise review | |
| Cook et al. | IgY–Immune component of eggs as a source of passive immunity for animals and humans | |
| JP2008044945A (en) | Probiotics as alternative drug confronting infectious disease | |
| BRPI0711073A2 (en) | increased titre due to vaccination in animals | |
| CN107337731A (en) | A kind of composite yolk antibody powder and its preparation production method for anti-dog and cat diarrhea | |
| CN112996808A (en) | Compositions and methods for treating acute diarrhea and intestinal infections in animals | |
| WO2004002527A1 (en) | Compositions against chicken coccidiosis | |
| EP0955061A1 (en) | Oral product for the prevention and therapy of porcine gastroenteric infections | |
| AU2016243967B2 (en) | Compositions and use of interleukin-10 peptides and anti-interleukin-10 antibodies | |
| CN104383528B (en) | Pig epidemic diarrhea inactivated vaccine and preparation method thereof | |
| CN102304182B (en) | Preparation method and use of enterotoxigenic Escherichia coli egg yolk antibody powder | |
| Ge et al. | Evaluation of different IgY preparation methods and storage stability as potential animal feed supplement. | |
| Zhang et al. | A review on the application of chicken immunoglobulin Y in aquaculture | |
| US20210252148A1 (en) | Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine | |
| TW200423950A (en) | Antidiarrheal composition | |
| CN104208675A (en) | Mixed freeze-dried powder for preventing chicken viral diseases and preparation method thereof | |
| Jabbari et al. | Effects of Protexin Probiotic and Aquablend Avian Antibody on Performance and Immune System of Broiler Chickens | |
| CN109223716B (en) | Quadruple yolk antibody soluble powder for resisting porcine epidemic diarrhea, swine fever, pseudorabies and transmissible gastroenteritis and preparation method thereof | |
| Khalf et al. | Efficacy of IgY immunoglobulin prepared in chicken egg yolk for the protection of chicken against necrotic enteritis | |
| Mushtaq et al. | Immunomodulatory and hepato-protective role of water based supplemented Bacillus clausii in broiler chicks | |
| CN103520719A (en) | Buccal antibody product and preparation method for same | |
| CN104162157A (en) | Composition for resisting swine fever, feed additive, and preparation method and use of feed additive | |
| AU775999B2 (en) | Growth promoting compositions for mammals and method of promoting the growth of mammals by using the same | |
| CN104208674B (en) | A kind of freeze-dried mixed powder of anti-porcine viral diseases and preparation method thereof | |
| EP2606741B1 (en) | Glycoprotein enriched composition as a food and feed additive and/or as a therapeutic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171110 |
|
| RJ01 | Rejection of invention patent application after publication |